1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours

https://doi.org/10.1016/j.annonc.2020.08.1145Get rights and content
Under an Elsevier user license
open archive

Cited by (0)